Exelixis narrows 2025 revenue guidance to $2.3B–$2.35B amid accelerated GI franchise expansion and new pivotal trials (NASDAQ:EXEL)
Group 1 - The article does not provide any relevant content regarding the company or industry [1]
Group 1 - The article does not provide any relevant content regarding the company or industry [1]